title: The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis.
abstract: Gastric emptying was measured in 9 diabetic patients with autonomic neuropathy (Group 1) and 8 normal controls (Group 2) on 4 occasions after swallowing placebo, 0.5, 1.0 or 2.0 mg of the newly developed prokinetic drug renzapride given double-blind and in random order. The liquid component of the test meal was labelled with In113m and the solid with Tc99m. Liquid emptying was uni-exponential. Solid emptying comprised an initial lag phase, followed by a linear component. Following placebo, the mean lag phase of solid emptying was 40 +/- 7 (S.E.M.) min in Group 1 and 16 +/- 2 min in Group 2 (P less than 0.01). In Group 1 subjects renzapride reduced the mean lag phase by 20-26 min at all doses (P less than 0.01). No effect was seen in Group 2. The linear rate of solid emptying was similar in both groups (0.9 +/- 0.1 and 1.0 +/- 0.2%/min) and was not altered by renzapride. Mean liquid t1/2 was similar in Groups 1 and 2 after placebo (30 +/- 6 and 29 +/- 4 min, respectively) and was decreased with increasing doses of renzapride in both groups. No adverse effects were encountered in any subjects. Renzapride may be useful in the treatment of diabetic gastroparesis.
authors.affiliation: Department of Medicine, Western General Hospital, Edinburgh.
authors.forename: A D
authors.initials: AD
authors.lastname: Mackie
authors.forename: C
authors.initials: C
authors.lastname: Ferrington
authors.forename: S
authors.initials: S
authors.lastname: Cowan
authors.forename: M V
authors.initials: MV
authors.lastname: Merrick
authors.forename: J D
authors.initials: JD
authors.lastname: Baird
authors.forename: K R
authors.initials: KR
authors.lastname: Palmer
mesh_terms: D000328:Adult; D000368:Aged; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy / Q000503:physiopathology; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001643:Bridged Bicyclo Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D013272:Stomach Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D001549:Benzamides; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D012702:Serotonin Antagonists; C053006:renzapride